In this review we aim to describe primary and secondary mechanisms of anti-PD-1 resistance in patients with melanoma and summarize existing and potential therapeutic strategies, including combination therapies and epigenetic modulation approaches. The gene discussed is PDCD1; the disease is melanoma.